CP 532623
| 中文名称 | CP 532623 |
|---|---|
| 中文同义词 | 化合物 T15004;化合物 CP-532623 |
| 英文名称 | (2R,4S)-4-[Acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2H)-quinolinecarboxylic acid 1-methylethyl ester |
| 英文同义词 | (2R,4S)-4-[Acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-1(2H)-quinolinecarboxylic acid 1-methylethyl ester;CP 532623;1(2H)-Quinolinecarboxylic acid, 4-[acetyl[[3,5-bis(trifluoromethyl)phenyl]methyl]amino]-2-ethyl-3,4-dihydro-6-(trifluoromethyl)-, 1-methylethyl ester, (2R,4S)-;CP 532623 >=98% (HPLC);CP532623,CP 532623 |
| CAS号 | 261947-38-0 |
| 分子式 | C27H27F9N2O3 |
| 分子量 | 598.5 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 261947-38-0.mol |
| 结构式 | ![]() |
CP 532623 性质
| 熔点 | 101.8 °C |
|---|---|
| 沸点 | 523.8±50.0 °C(Predicted) |
| 密度 | 1.38±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 在DMSO中的溶解度为20mg/mL,澄清 |
| 酸度系数(pKa) | -0.93±0.40(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
| InChIKey | TUPKOWFPVAXQFP-OFNKIYASSA-N |
| SMILES | O=C(OC(C)C)N1C2=CC=C(C(F)(F)F)C=C2[C@@H](N(CC3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C(C)=O)C[C@H]1CC |
CETP
CP-532623 is highly lymphatically transported (28% of dose), and lymphatic transport is closely correlated with drug affinity for ex-vivo lymph lipoproteins or triglyceride emulsions and poorly relates to solubility in mixtures of lipoprotein core and/or surface lipids. CP-532623 alters the kinetics of lymph lipid transport and decreases lymph lipid transport in chylomicrons.
CP-532623 (50 mg; oral administration; adult male greyhound dogs) treatment substantially transports into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhances oral bioavailability (from 44 to 58%, respectively) and the proportion of the absorbed dose transports via the lymph (from 61 to 86% and from 68 to 83%, respectively). Lymphatic triglyceride transport is significantly lower in fed dogs administered CP-532623.
| Animal Model: | Adult male greyhound dogs (27-39 kg) |
| Dosage: | 50 mg |
| Administration: | Oral administration with a long-chain lipid formulation to fed lymphcannulated |
| Result: | Substantially transported into the lymphatic system (>25% dose) in fed and fasted dogs. Food enhanced oral bioavailability and the proportion of the absorbed dose transported via the lymph. |
安全信息
| WGK Germany | 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 危险性类别 | 急性毒性 类别4 经口 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-123039 | CP-532623 | 261947-38-0 | 1 mg | 2550元 |
| 2025/05/22 | HY-123039 | CP 532623 CP-532623 | 261947-38-0 | 5mg | 2160元 |
